Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas

Feasibility of Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas

The investigators hypothesize that this study will show that sufficient lymphocyte stem cell can be harvested prior chemoradiation and be reinfused back after treatment, and at least 5 of the 10 patients (50%) will achieve an absolute increase of lymphocyte counts of 300 cells/mm^3 four weeks after stem cell reinfusion in high grade glioma patients.

Study Overview

• Status: Withdrawn
• Conditions: Astrocytoma; Ependymoma; Oligodendroglioma; Brainstem Glioma; Mixed Glioma; Optic Nerve Glioma
• Intervention / Treatment: Drug: Temozolomide; Radiation: Radiation therapy; Procedure: Stem cell infusion; Procedure: Stem cell collection

• Study Type: Interventional
• Phase: Early Phase 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Histologically confirmed newly diagnosed high grade glioma by pathology (WHO grade III or IV).
• At least 18 years of age.
• Karnofsky performance status ≥ 60%

• Normal bone marrow and organ function as defined below:

  • Absolute neutrophil count ≥ 1,500/mcl
  • Platelets ≥ 100,000/mcl
  • Hematocrit ≥ 30%
  • Absolute lymphocyte count ≥ 1000/mcl Blood transfusions are permitted to allow potential participant to meet these criteria.
• Post-operative treatment plan must include standard radiation and temozolomide.
• Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
• Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

• Prior treatment with radiation therapy, chemotherapy, immunotherapy, biologic agents (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, TIL, LAK, or gene therapy), or hormonal therapy. Glucocorticoid therapy is allowed.
• Anti-VEGF therapy within 6 weeks of registration.
• A history of other malignancy ≤ 5 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or carcinoma in situ of the cervix.
• Currently receiving any investigational agents that might affect lymphocytes. Patients receiving Novocure are allowed on study.
• A history of allergic reactions attributed to compounds of similar chemical or biologic composition to filgrastim or plerixafor or other agents used in the study.
• Fresh CNS bleed as evident by MRI or CT.
• Contraindicated for anticoagulation.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
• Known HIV-positivity.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Focal RT, Temozolomide, Stem Cell Collection/Reinfusion; Autologous stem cell collection will be performed 1-4 days prior to initiating radiation therapy and temozolomide; Focal radiation therapy: standard of care dose daily for approximately 6 weeks; Temozolomide: standard of care dose by mouth daily for 6 weeks with radiation; 2-7 days after the end of the radiation therapy and temozolomide the stem cells will be reinfused into the patient; Temozolomide: standard of care dose by mouth on days 1-5 every 28 days for 6 months following a 4-6 week rest period after the initial radiation and temozolomide

Drug: Temozolomide; Other Names: Temodar®; Radiation: Radiation therapy; Procedure: Stem cell infusion; Procedure: Stem cell collection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Efficacy of lymphocyte stem cell harvesting and reinfusion in patients as measured by the number of patients from whom 1-5x10e6 lymphocyte stem cells are collected and successfully reinfused without an adverse event	The study will provide preliminary evidence of efficacy if ≥5 of 10 patients (50%) achieve an increase over baseline in absolute lymphocyte counts (ALC) ≥300 cells/mm3 at 4 weeks after reinfusion from their baseline lymphocyte counts.	Completion of follow-up of all patients who received stem cell reinfusions (estimated to be 15 months)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of lymphocyte stem cells that can be harvested from this patient population		Completion of follow-up of all patients who received stem cell reinfusions (estimated to be 15 months)
Proportion of patients who have an increase in lymphocyte of ≥300 cells/mm^3 after autologous stem cell reinfusion.		4 weeks after stem cell reinfusion
Duration of lymphocyte rise following stem cell reinfusion		Up to 6 months after stem cell reinfusion (approximately 9 months)
Changes in lymphocyte subtypes following collection and reinfusion	Lymphocyte subtypes will be monitored by flow cytometry at the time of stem cell collection, prior to autologous stem cell reinfusion, and then monthly for 6 months.	Up to 6 months after stem cell reinfusion (approximately 9 months)
Changes in series of cytokine levels following collection and reinfusion	Cytokine levels will be checked by ELISPOT at the time of stem cell collection, weekly during radiation therapy/temozolomide (up to 6 weeks), prior to autologous stem cell reinfusion, and then monthly for 6 months.	Up to 6 months after stem cell reinfusion (approximately 9 months)
Safety and toxicities with stem cell collection and reinfusion as measured by grade and frequency of adverse events	the descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all adverse event/toxicity reporting.	Up to 6 months after stem cell reinfusion (approximately 9 months)

Collaborators and Investigators

• Sponsor: Washington University School of Medicine
• Investigators: Principal Investigator: Jian Li Campian, M.D., Ph.D., Washington University School of Medicine

Publications and helpful links

Helpful Links

• Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Study record dates

Study Major Dates

• Study Start: January 1, 2017
• Primary Completion (Anticipated): February 1, 2018
• Study Completion (Anticipated): February 1, 2018

Study Registration Dates

• First Submitted: November 23, 2016
• First Submitted That Met QC Criteria: November 23, 2016
• First Posted (Estimate): November 29, 2016

Study Record Updates

• Last Update Posted (Actual): February 20, 2017
• Last Update Submitted That Met QC Criteria: February 16, 2017
• Last Verified: February 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Neoplasms, Glandular and Epithelial; Eye Diseases; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Nervous System Neoplasms; Optic Nerve Diseases; Cranial Nerve Diseases; Peripheral Nervous System Neoplasms; Cranial Nerve Neoplasms; Optic Nerve Neoplasms; Glioma; Ependymoma; Astrocytoma; Oligodendroglioma; Optic Nerve Glioma; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Temozolomide
• Other Study ID Numbers: 15-x135